Organigram (TSE:OGI) Given New C$3.25 Price Target at Atb Cormark Cm

Organigram (TSE:OGI) had its price objective reduced by investment analysts at Atb Cormark Cm from C$3.50 to C$3.25 in a research report issued to clients and investors on Wednesday,BayStreet.CA reports. The firm currently has an “outperform” rating on the stock. Atb Cormark Cm’s price objective would indicate a potential upside of 82.58% from the company’s previous close.

Separately, Canaccord Genuity Group set a C$3.00 price target on Organigram and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of C$3.13.

Organigram Price Performance

Shares of TSE OGI traded down C$0.11 during midday trading on Wednesday, hitting C$1.78. The company had a trading volume of 668,677 shares, compared to its average volume of 257,718. The firm has a market capitalization of C$239.34 million, a price-to-earnings ratio of -9.18, a price-to-earnings-growth ratio of 0.42 and a beta of 1.97. Organigram has a twelve month low of C$1.22 and a twelve month high of C$3.09. The business has a 50-day simple moving average of C$2.31 and a two-hundred day simple moving average of C$2.30. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.